These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27610894)

  • 1. Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.
    Aspeslagh S; Awada A; S Matos-Pita A; Aftimos P; Bahleda R; Varga A; Soria JC
    Anticancer Drugs; 2016 Nov; 27(10):1021-7. PubMed ID: 27610894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
    Aspeslagh S; Stein M; Bahleda R; Hollebecque A; Salles G; Gyan E; Fudio S; Extremera S; Alfaro V; Soto-Matos A; Soria JC
    Anticancer Drugs; 2017 Mar; 28(3):341-349. PubMed ID: 27977433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.
    Mateos MV; Cibeira MT; Richardson PG; Prosper F; Oriol A; de la Rubia J; Lahuerta JJ; García-Sanz R; Extremera S; Szyldergemajn S; Corrado C; Singer H; Mitsiades CS; Anderson KC; Bladé J; San Miguel J
    Clin Cancer Res; 2010 Jun; 16(12):3260-9. PubMed ID: 20530693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
    Said R; Kakadiaris E; Piha-Paul S; Fu S; Falchook G; Janku F; Wheler JJ; Zinner R; Hong DS; Kurzrock R; Tsimberidou AM
    Cancer Chemother Pharmacol; 2016 May; 77(5):1097-102. PubMed ID: 27085994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an Innovative Therapies for Children with Cancer (ITCC) study.
    Geoerger B; Estlin EJ; Aerts I; Kearns P; Gibson B; Corradini N; Doz F; Lardelli P; Miguel BD; Soto A; Prados R; Vassal G
    Eur J Cancer; 2012 Feb; 48(3):289-96. PubMed ID: 22119199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas.
    Salazar R; Plummer R; Oaknin A; Robinson A; Pardo B; Soto-Matos A; Yovine A; Szyldergemajn S; Calvert AH
    Invest New Drugs; 2011 Dec; 29(6):1406-13. PubMed ID: 20623160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
    Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
    Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
    Spicer J; Irshad S; Ang JE; Enting D; Kristeleit R; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):17-27. PubMed ID: 27872953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma.
    Plummer R; Lorigan P; Brown E; Zaucha R; Moiseyenko V; Demidov L; Soriano V; Chmielowska E; Andrés R; Kudryavtseva G; Kahatt C; Szyldergemajn S; Extremera S; de Miguel B; Cullell-Young M; Calvert H
    Br J Cancer; 2013 Sep; 109(6):1451-9. PubMed ID: 23989947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.
    Maroun JA; Belanger K; Seymour L; Matthews S; Roach J; Dionne J; Soulieres D; Stewart D; Goel R; Charpentier D; Goss G; Tomiak E; Yau J; Jimeno J; Chiritescu G;
    Ann Oncol; 2006 Sep; 17(9):1371-8. PubMed ID: 16966366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors.
    Salazar R; Cortés-Funes H; Casado E; Pardo B; López-Martín A; Cuadra C; Tabernero J; Coronado C; García M; Soto Matos-Pita A; Miguel-Lillo B; Cullell-Young M; Iglesias Dios JL; Paz-Ares L
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):75-83. PubMed ID: 23645288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
    Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
    Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies.
    Faivre S; Chièze S; Delbaldo C; Ady-Vago N; Guzman C; Lopez-Lazaro L; Lozahic S; Jimeno J; Pico F; Armand JP; Martin JA; Raymond E
    J Clin Oncol; 2005 Nov; 23(31):7871-80. PubMed ID: 16172454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Mateos MV; Prosper F; Martin Sánchez J; Ocio EM; Oriol A; Motlló C; Michot JM; Jarque I; Iglesias R; Solé M; Martínez S; Kahatt C; Fudio S; Corral G; Zeaiter A; Montilla L; Ribrag V
    Cancer Med; 2023 Feb; 12(4):3999-4009. PubMed ID: 36127823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.
    Schöffski P; Guillem V; Garcia M; Rivera F; Tabernero J; Cullell M; Lopez-Martin JA; Pollard P; Dumez H; del Muro XG; Paz-Ares L
    Mar Drugs; 2009; 7(1):57-70. PubMed ID: 19370171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
    Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
    Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors.
    Weekes CD; Rosen LS; Capasso A; Wong KM; Ye W; Anderson M; McCall B; Fredrickson J; Wakshull E; Eppler S; Shon-Nguyen Q; Desai R; Huseni M; Hegde PS; Pourmohamad T; Rhee I; Bessudo A
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):339-351. PubMed ID: 29905898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
    Rosen PJ; Sweeney CJ; Park DJ; Beaupre DM; Deng H; Leitch IM; Shubhakar P; Zhu M; Oliner KS; Anderson A; Yee LK
    Clin Cancer Res; 2010 May; 16(9):2677-87. PubMed ID: 20406832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.